Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA risk communication strategy

This article was originally published in The Tan Sheet

Executive Summary

The Risk Communication Advisory Committee discusses the agency's draft risk communication strategic plan and offers further advice on strategic priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. Presentations from the public are scheduled between 1 p.m. and 2 p.m. the first day and 10:30 a.m. to 11:30 a.m. the next day during the meeting at an FDA facility in Rockville, Md., according to a March 5 Federal Register notice. At its previous meeting, the committee emphasized that FDA should assess its communications to ensure safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)

You may also be interested in...



FDA Risk Communication Research May Follow Critical Path To Avoid OMB

FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts

Grail Starts PATHFINDER Trial To Evaluate Multi-Cancer Blood Test For Early Cancer Detection

Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Topics

UsernamePublicRestriction

Register

PS102730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel